Recent advances in quantitative neuroproteomics

Abstract

The field of proteomics is undergoing rapid development in a number of different areas including improvements in mass spectrometric platforms, peptide identification algorithms and bioinformatics. In particular, new and/or improved approaches have established robust methods that not only allow for in-depth and accurate peptide and protein identification and modification, but also allow for sensitive measurement of relative or absolute quantitation. These methods are beginning to be applied to the area of neuroproteomics, but the central nervous system poses many specific challenges in terms of quantitative proteomics, given the large number of different neuronal cell types that are intermixed and that exhibit distinct patterns of gene and protein expression. This review highlights the recent advances that have been made in quantitative neuroproteomics, with a focus on work published over the last five years that applies emerging methods to normal brain function as well as to various neuropsychiatric disorders including schizophrenia and drug addiction as well as of neurodegenerative diseases including Parkinson’s disease and Alzheimer’s disease. While older methods such as two-dimensional polyacrylamide electrophoresis continued to be used, a variety of more in-depth MS-based approaches including both label (ICAT, iTRAQ, TMT, SILAC, SILAM), label-free (label-free, MRM, SWATH) and absolute quantification methods, are rapidly being applied to neurobiological investigations of normal and diseased brain tissue as well as of cerebrospinal fluid (CSF). While the biological implications of many of these studies remain to be clearly established, that there is a clear need for standardization of experimental design and data analysis, and that the analysis of protein changes in specific neuronal cell types in the central nervous system remains a serious challenge, it appears that the quality and depth of the more recent quantitative proteomics studies is beginning to shed light on a number of aspects of neuroscience that relates to normal brain function as well as of the changes in protein expression and regulation that occurs in neuropsychiatric and neurodegenerative disorders.

Circulating biomarkers in schizophrenia: a proteomics perspective

“…Throughout the years researchers have turned to other methodologies that can measure quantitative levels of the entire set of proteins, and that can be divided into two main groups: (i) labelling techniques, which require the chemical, metabolic or enzymatic stable isotopic labelling of the samples prior to MS analysis; (ii) label-free techniques, which are gaining increasing interest due to improvements in accuracy and sensitivity of MS instruments and data processing algorithms [33].…”

Peptidomics of Urine and Other Biofluids for Cancer Diagnostics

“…Via continual interactions, CSF contains molecules that can reflect many of the processes of the central nervous system (14 ). Proteomic efforts have been aimed at characterizing the CSF peptidome to discover potential biomarkers for neurodegenerative conditions, neuropsychiatric disorders, traumatic brain injury, brain tumors, and aging-related conditions (23,24 ). Wijte et al used an enhanced mass spectrometry-based approach for both free peptides and peptides bound to proteins to evaluate postmortem CSF from patients with Alzheimer disease and identified a series of candidate peptides for its diagnosis, such as VGF, nerve growth factor, and C4 complement precursor (25 ).…”

Targeting Emotion Circuits with Deep Brain Stimulation in Refractory Anorexia Nervosa

“…At the current stage of development, no multiplex immunoassaybased approaches that target 410 analytes have proved sufficiently sensitive to detect beta-amyloid and tau in CSF at the level achieved when optimizing conditions to simultaneously measure these analytes (Kang et al, 2012). Mass spectrometric-based assays offer an unbiased discovery approach (Craft et al, 2013); studies are underway with the same CSF ADNI samples allowing for a unique contrast to the multiplex immunoassay approach. Informatics and pathway analysis approaches can also be used to analyze proteomic data, but there is a tension between application of such methodologies and reproducibility of measures within a proteomic platform.…”